Vertex Pharmaceuticals Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases, primarily cystic fibrosis (CF), sickle cell disease (SCD), beta thalassemia, and acute pain. The company operates in a single segment: pharmaceuticals.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $2,986.9 million | $2,770.2 million |
| Net Income | $1,031.4 million | $646.3 million |
| Diluted EPS | $4.02 | $2.49 |
| Operating Cash Flow | $1,428.1 million | $818.9 million |
| Cash & Marketable Securities | $12,996.6 million | $12,320.4 million (Dec 31, 2025) |
| Working Capital | $7,849.7 million | $7,339.8 million (Dec 31, 2025) |
| Effective Tax Rate | 17.7% | 11.5% |
Revenue Breakdown: CF products generated $2,915.0 million (97% of total), driven by TRIKAFTA/KAFTRIO ($2,354.7 million) and ALYFTREK ($424.4 million). Non-CF products (CASGEVY and JOURNAVX) contributed $71.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 8% year-over-year, driven by strong CF performance and growth in non-CF products (CASGEVY up 202%, JOURNAVX up significantly from launch).
- Profitability Surge: Net income increased 60% to $1.03 billion. This was significantly aided by the absence of a $379.0 million intangible asset impairment charge recorded in Q1 2025 related to the discontinued VX-264 program.
- Expense Management: Total costs and expenses decreased 14% to $1.85 billion. R&D expenses declined slightly (2%) to $961.6 million, while SG&A increased 25% to $493.7 million due to commercial investments for JOURNAVX and povetacicept.
- Share Repurchases: The company repurchased 0.7 million shares for $344.5 million in Q1 2026. Approximately $3.0 billion remains available under the 2025 Share Repurchase Program.
Outlook, Risks, and Contingencies
- Pipeline Progress: The company submitted a rolling Biologics License Application (BLA) for povetacicept (IgA nephropathy) in March 2026, expecting an expedited FDA review. Regulatory submissions for ALYFTREK and TRIKAFTA in younger pediatric CF populations are ongoing.
- Legal Contingency: Royalty Pharma plc (RP) initiated confidential arbitration in October 2025 alleging the royalty burden on ALYFTREK is approximately 8%, contrary to Vertex's position of 4%. Vertex intends to vigorously defend its position. No material loss contingency has been accrued.
- Tax Environment: The U.S. enacted H.R.1 in July 2025, modifying the tax framework (e.g., immediate R&D deduction). While not materially impacting Q1 2026, future guidance may affect effective tax rates.
- Liquidity: The company maintains a strong liquidity position with nearly $13 billion in cash and marketable securities and an undrawn $500 million credit facility maturing in 2027.
Investor Verification Checklist
- Verify the outcome of the arbitration with Royalty Pharma regarding ALYFTREK royalty rates (4% vs. 8% claim).
- Monitor the FDA acceptance and review timeline for the povetacicept BLA for IgA nephropathy.
- Track the commercial uptake and reimbursement status of JOURNAVX and CASGEVY in new geographies.
- Review future guidance on the impact of H.R.1 tax legislation on effective tax rates and cash taxes.
- Confirm the timeline for the interim analysis of the AMPLITUDE trial for inaxaplin (APOL1-mediated kidney disease), expected in early 2027.